Q1 2020 Earnings Call
[music].
The conference. Please press Star then the zero by your Touchtone telephone as a reminder, this conference is being recorded I would now like turn the conference over to your host Ms., Susan Hubbard SVP of public Affairs and Investor Relations. Please proceed.
Thank you Nita and thank you all for joining us for the Exelixis first quarter 2020 financial results Conference call.
Joining me on todays call or Mike Morrissey, our President and CEO, Chris Center, our Chief Financial Officer, PJ Haley, our executive Vice President of commercial and diesel truck, our Chief Medical Officer, who together will review, our corporate financial commercial and development progress for the first quarter 2020 ended March 30 Onest two.
Thousand 20.
During the call today, we will refer to financial measures not calculated according to generally accepted accounting principles. Please refer to today's press release, which is posted on our website for an explanation of our reasons for using such non-GAAP measures as well as tables deriving these measures from our GAAP results.
During the course of this presentation, we will be making forward looking statements regarding future events in the future performance of the company. This includes statements about possible developments regarding discovery product development regulatory commercial financial and strategic matters as well as the impact of the Cobas 19 pandemic on Exelixis is business operations.
Actual events or results could of course differ materially we refer you to the documents we file from time to time with the SEC with under the heading risk factors identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing today, including without limitation risks and uncertainties.
Related to product commercial success market competition regulatory review and approval processes conducting clinical trials compliance with applicable regulatory requirements are dependent on collaboration partners and the level of costs associated with discovery product development business development and commercialization activities and now with.
I will turn it over to Mike Alright, Thank you Susan and thanks to everyone for joining us on the call today Exelis has had a strong first quarter across all components of our business.
I'll retire team working remotely as a cohesive unit continues to navigate the challenges of the coded 19 pandemic with a singular focus of ensuring that we do everything in our power to maximize access to accomplish lanthanum for cancer patients through either commercial channels or clinical trials.
We recognize that cancer patients need to take the treatments and as directed and we've gone to Greek links to ensure patient access to our medicines in these challenging times.
We'll keep our prepared remarks shorts and address your questions as the main part of todays update. Please see our press release that was issued an hour ago for our first quarter 2020 financial results and extensive list of corporate highlights.
Before we review the performance of our business in the quarter I want to provide a brief update on how Exelixis has responded to cope with 19 at an organizational level. Our top priority is the health and safety of the Exelixis workforce. So we implemented our work from home policy ahead of the California sold from please order and quickly pivoted our steel.
It was forced to move to virtual touch points with prescribers.
At the same time, the 600 plus members of our Exelixis team have engaged in the fight against overnight.
Keith.
Yes.